PureSense INDICATIONS AND SUMMARY TABLE TEOSYAL. TEOSYAL PureSense First Lines. TEOSYAL PureSense. TEOSYAL PureSense. TEOSYAL PureSense.

Transcription

1 M RGET RGET PTE 877 QUR SWSS VT PPE T BEUTY TS SUMMRY TBE First ines Global ction H concentration 20 mg/g 22 mg/g idocaine concentration eedle 30G 1/2 30G 1/2 27G 1/2 27G 1/2 27G 1/2 23G 1 ndications orrection of superficial wrinkles: fine lines and wrinkles on thin skin Filling of all moderately pronounced wrinkles on the full face Filling deep wrinkles njection area Papillary dermis Reticular dermis eep dermis Volume-creating capability H Y U R EFFETVE SFE G-STG eep dermis Subdermis or pre-periosteal Blister pack 2 x 0.7 m 2 x 1.2 m 1 x 3 m Estimated duration before touch up* 6 months up to 9 months 9 months up to 9 months 12 months up to 18 months when efficacy meets comfort * verage duration depends on several factors: patient's skin type, severity of the wrinkle to be corrected, type of injection and the volume injected. E PTM MFRT Hypodermis reation of volume (cheekbones, cheeks, chin, temporal area) es harmilles - Rue de yon, H 1203 Genève Tél. : +41 (0) Fax : +41 (0) info@teoxane.com REF : /03 Harmonization of Redefinition of volume and lip facial contours contour orrection of very deep wrinkles in thick skin

2 RGET PTE 877 linically proven Results The most complete dermal fillers range with lidocaine the1st barrier Fear of pain QUR of patients towards injections METHGY Multicentrical study, r Trevidic and r laude (France, 2010) 32 patients 63% of patients type (Fitzpatrick skin scale) psos consumer study 2008 Split face design injection of nasolabial folds and lips with vs (, et ) ntense volume Pain assessment measured by VS* international scale The gentle way to give volume SGFT REUT F THE PTET'S P P SSESSEMET ips enhancement VS SE H Y U R EFFETVE SFE G-STG E 50 n-depth filling 40 PTM MFRT - 68,7% 30 Global ction Simplified filling PTET STSFT - 66,5% 20 «o pain» threshold reached after 5 min 10 First ines Soft lines 0 TESY BEFRE of patients injected with TESY are willing to be re-injected*. 1ml syringe injected asolabial folds, marionette lines 2x1ml syringes injected TESY 5 M FTER JET n-vitro test reproducing the action of oxidative stress in the skin When injected in the skin, hyaluronic acid gels suffer from a strong oxidative stress (skin inflammatory response) accelerating the % of remaining elasticity G 96 % deterioration of the product. 95 GRE 99% 1 MTH FTER oss of elasticity due to exposition to oxidative stress asolabial folds TESY n optimized durability 100% of patients injected satisfied by the aesthetic results of the treatment. GRE found injection significantly less painful than an injection without lidocaine*. GRE V 10 TESY URG JET mmediate and ong-lasting Results GRE V 9 patients out of (average perceived pain) % Thanks to Teoxane aboratories know-how 80 in the conception of hyaluronic acid based 75 dermal fillers, 70 products offer a better protection against oxidative stress in comparison % with other dermal fillers containing the same 50 H monophasic gel (H 24mg/ml + lidocaine 0,3%) H biphasic gel (H 20mg/ml + lidocaine 0,3%) concentration of lidocaine. (H 25mg/ml + lidocaine 0,3%) *Visual nalogic Scale * Multicentrical study done on 32 patients by octors Trevidic and laude, specialists in Plastic, Reconstructive and esthetics Surgery

3 KSS EW FRMUT PTURE : R E PVÁ (Slovakia) PTURE : R E PVÁ (Slovakia) BEFRE FTER Excellent patient satisfaction: 94% would recommend a treatment with ew Formulation (1) 82% would do it again (1) Strong Resistance 40 High cohesivity for a long-lasting efficacy (2) specifically adapted to the mobility of the lips deal elastic profile for a smooth gel, easy and comfortable to inject under control Enhanced safety and tolerability for a delicate and highly exposed area Resistance to pressure and skin movements ohesivity (.s.) EW FRMUT Solid (1) Post-market clinical investigation on Teosyal ew Formulation made in ctober 2012 on 26 patients (women only, average age 41 years old) followed by 13 practitioners (2) urability from 9 to 12 months (3) eeded force to achieve a shape distortion (High modulus = hard to deform) G (Pa), at rest Elasticity modulus (3)

4 global approach to recover a natural smile! EW FRMUT Philtrum Redensity [ ] ermis redensification ip corners ips and lip contour Global ction / asolabial folds Marionnette lines TEXE T SURE EW FRMUT ip enhancement H concentration: 25 mg/ml idocaine: 0,3% (), Box: / eedle: 27G½" Redensity [ ] ermis redensification on cross-linked H concentration: 15 mg/ml idocaine 0,3% ermo-restructuring omplex* Box: & 1 x 3 m / eedle: 30G½" Global ction Simplified filling H concentration: 25 mg/ml idocaine: 0,3% (), Box: / eedle: 30G½" n-depth filling H concentration: 25 mg/ml idocaine: 0,3% (), Box: / eedle: 27G½" REF: /01 EMHEU ESG SEPTEMBER 2013 (*) Patent pending

5 Pictures: r Kieren Bong, UK Pictures: r Kieren Bong, UK EW 2x1ml with a 27G½" needle BEFRE Easy to inject: lower extrusion force and more malleability for a better control of the injection with a 27G½" needle. Respect the depth of injection: subcutaneous and pre-periosteal High cohesivity: long-lasting effect over 18 months (2) Unique viscoelasticity: ideal remodeling gel dapted to your patients needs: less quantity for smaller corrections (1) fter 2 weeks, 2 visits, 3 syringes of 3ml (2) on-surgical facial contouring using a combination of the hyaluronic acid filler TESY (,, and ) by eaders Skin Group ak Kyung Rho. The linical Journal of the ssociation of Korean ermatologists Vol. 15 o. 4 VEMBER 2012 FTER (1)

6 Scientific art applied to volumising and contouring Volume recovery for wide areas Volume creation for targeted areas Malar rea Facial contour heekbones hin TEXE T SURE REF: /01 EMHEU ESG SEPTEMBER 2013 H oncentration: 22 mg/m idocaine 0,3% () Box / eedle: / 27G ½ " 1 x 3 m / 23G 1 " H oncentration: 25 mg/m idocaine 0,3% () Box / eedle: / 25G 1 " 2 x 1.2 m / 25G 1 "